Surgery – Means for introducing or removing material from body for... – Treating material introduced into or removed from body...
Reexamination Certificate
2005-03-22
2010-11-23
Lucchesi, Nicholas D (Department: 3763)
Surgery
Means for introducing or removing material from body for...
Treating material introduced into or removed from body...
C604S514000, C604S103010
Reexamination Certificate
active
07837670
ABSTRACT:
The present invention is directed to the treatment of various ailments associated with the prostate gland, including benign prostate hypertrophy (BPH), cancer and chronic inflammatory diseases. The present invention describes, inter alia, devices, methods and therapeutic agents for the treatment of prostatic ailments.
REFERENCES:
patent: 3977408 (1976-08-01), MacKew
patent: 5007897 (1991-04-01), Kalb et al.
patent: 5112305 (1992-05-01), Barath et al.
patent: 5242397 (1993-09-01), Barath et al.
patent: 5336178 (1994-08-01), Kaplan et al.
patent: 5419763 (1995-05-01), Hildebrand
patent: 5681281 (1997-10-01), Vigil et al.
patent: 5713863 (1998-02-01), Vigil et al.
patent: 5746716 (1998-05-01), Vigil et al.
patent: 5843016 (1998-12-01), Lugnani et al.
patent: 5873852 (1999-02-01), Vigil et al.
patent: 6102904 (2000-08-01), Vigil et al.
patent: 6210392 (2001-04-01), Vigil et al.
patent: 6547803 (2003-04-01), Seward et al.
patent: 6656155 (2003-12-01), Freyman
patent: 6692493 (2004-02-01), McGovern et al.
patent: 6695839 (2004-02-01), Sharkey
patent: 2002/0162521 (2002-11-01), Shkolnikov et al.
patent: 2003/0092689 (2003-05-01), Escandon et al.
patent: 2003/0114793 (2003-06-01), Freyman
patent: 2004/0002647 (2004-01-01), Desai
patent: 2004/0010301 (2004-01-01), Kindlein et al.
patent: 2004/0024355 (2004-02-01), Tsukada
patent: 2004/0064094 (2004-04-01), Freyman
patent: 2004/0215181 (2004-10-01), Christopherson et al.
patent: 0044804 (1982-01-01), None
patent: WO 97/31611 (1997-09-01), None
patent: WO 97/36631 (1997-10-01), None
patent: WO 99/59666 (1999-11-01), None
patent: WO 03/033045 (2003-04-01), None
patent: WO 03/051442 (2003-06-01), None
G. Kerr Whitfield et al., “Steroid Hormone Receptors: Evolution, Ligands, and Molecular Basis of Biologic Function,”Journal of CellularBiochemistrySupplements,32/33 (1999): 110-122.
Yasuhiro Shibata et al., “Comparison of Histological Compositions and Apoptosis in Canine Spontaneous Benign Prostatic Hyperplasia Treated with Androgen Suppressive Agents Chlormadinone Acetate and Finasteride,”Journal of Urology,165 (2001): 289-293.
Ann W. Hsing et al., “Hormones and Prostate Cancer: Current Perspectives and Future Directions,”The Prostate,52 (2002): 213-235.
Christopher K. Glass et al., “The coregulator exchange in transcriptional functions of nuclear receptors,”Genes&Development,14 (2000): 121-141.
Natasha Kyprianou et al., “Activation of Programmed Cell Death in the Rat Ventral Prostate after Castration,”Endocrinology,122 (1988): 552-562.
Partha P. Banerjee et al., “Lobe-Specific Apoptotic Cell Death in Rat Prostate after Androgen Ablation by Castration,”Endocrinology,136 (1995): 4368-4376.
Kaitkanoke Sirinarumitr et al., “Finasteride-induced prostatic involution by apoptosis in dogs with benign prostatic hypertrophy,”Am.J. Vet. Res.,63 (2002): 495-498.
K. Suzuki et al., “Estimation of Canine Prostatic Volume: Nomogram Based on Prostatic Cubic Volume,”International Urology and Nephrology,30 (1998): 725-730.
D. Tavian et al., “Androgen receptor mRNA under-expression in poorly differentiated human hepatocellular carcinoma,”Histology and Histopathology,17 (2002): 1113-1119.
Gerald Sufrin et al., “A New Model for Studying the Effect of Drugs on Prostatic Growth 1. Antiandrogens and Dna Synthesis,” 11 (1973): 45-54.
Nelson Stone, “Flutamide in Treatment of Benign Prostatic Hypertrophy,”Urology,Supplement, 34 (1989): 64-68.
Arihiro Tomura et al., “The Subnuclear Three-dimensional Image Analysis of Androgen Receptor Fused to Green Fluorescence Protein,”Journal of Biological Chemistry,276 (2001): 28395-28401.
Manjunath S. Si-Let et al., “Metabolism of the antiandrogenic Drug (Flutamide) by Human CYP 1 A2,”Drug Metalbolism and Disposition,25 (1997): 1298-1303.
Zhong Zuo et al., “Flutamide-Hydroxypropyl-β-cyclodextrin Comples: Formulation, Physical Characterization, and Adsorption Studies using the Caco-2 in vitro Model,”J. Pharm. Pharmaceut. Sci,3 (2000): 220-227.
D.R. Greene et al., “Sonographic Measurements of Transition Zone of Prostate in Men with and without Benign Prostatic Hyperplasia,”Urology,36 (1990): 293-299.
Martha K. Terris et al., “Determination of Prostate Volume by Transrectal Ultrasound,”Journal of Urology,145 (1991): 984-987.
Hiroki Watanabe et al., “Measurements of Size and Weight of Prostate by Means of Transrectal Ultrasonotomography,”Tohoku J. Exp. Med,114 (1974): 277-285.
A.R. Zlotta et al., “The importance of measuring the prostatic transition zone: an anatomical and radiological study,”BJU International,84 (1999): 661-666.
Theodore L. Deweese et al., “A Phase I Trial of CV706, a Replication-competent, PSA Selective Oncolytic Adenovirus, for the Treatment of Locally Recurrent Prostate Cancer following Radiation Therapy,”Cancer Research,61 (2001): 7464-7472.
Louis L. Pisters et al., “Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer,”Clinical Cancer Research,10 (2004): 2587-2593.
Martha K. Terris, “Ultrasonography and Biopsy of the Prostate,” inCampbell's Urology,vol. 4 (Saunders: Philadelphia, 2002), pp. 3038-3054.
Mark Frydenberg et al., Benign Prostate Disorders, Chap. 9. Nov. 9, 2004. http://www.endotext.org/male/male9/male9.htm.
Bonham David B.
Boston Scientific Scimed Inc.
Bouchelle Laura A
Lucchesi Nicholas D
Mayer Stuart H.
LandOfFree
Methods and devices for delivering therapeutic agents into... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and devices for delivering therapeutic agents into..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and devices for delivering therapeutic agents into... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4197450